Serum Total Ganglioside Level Correlates With Clinical Course in Melanoma Patients After Immunotherapy With Therapeutic Cancer Vaccine

Journal of Immunotherapy

Volumn 26, Issue 3, 2003, Pages 277-285

  Ravindranath, Mepur H ^a   Hsueh, Eddy C ^a   Verma, Meena ^a   Ye, Wei ^a   Morton, Donald L ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

Active specific immunotherapy; Cancer vaccine; In transit melanoma; Serum total ganglioside level

Indexed keywords

CANCER VACCINE; CANVAXIN; GANGLIOSIDE; GANGLIOSIDE GD 1B; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GANGLIOSIDE GT 1B;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT MONITORING; PRIORITY JOURNAL; SURVIVAL TIME; VACCINATION;

ADULT; CANCER VACCINES; FEMALE; GANGLIOSIDES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA;

EID: 0037500834     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200305000-00011     Document Type: Article

References (35)

1. Silver HKB, Rangel DM, Morton DL. Serum sialic acid elevations in malignant melanoma patients. Cancer. 1978; 41:1497-1499.
2. 3 shedding by human malignant melanoma cells. Int J Cancer. 1989; 44:155-160.
3. Portoukalian J, Zwingelstein G, Abdul-Malek N, et al. Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun. 1978; 85:916-920.
4. Ladisch S, Wu Z. Detection of a tumor-associated ganglioside in plasma of patients with neuroblastoma. Lancet. 1985; i:136-138.
5. Ladisch S, Wu Z, Feig S, et al. Shedding of GD2 ganglioside by human neuroblasoma. Int J Cancer. 1987; 39:73-76.
6. Perez CA, Ravindranath MH, Soh D, et al. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J. 2002; 8:384-394.
7. Ravindranath MH, Wood TF, Soh, D, et al. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology. 2002; 45:10-21.
8. Barth A, Hoon DSB, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 1994; 54:3342-3345.
9. Hsueh EC, Nathanson L, Foshag LJ, et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer. 1999; 85:2160-2169.
10. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19:3635-3648.
11. Tsuchida T, Ravindranath MH, Saxton RE, et al. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res. 1987; 7:1278-1281.
12. Morton DL, Ravindranath MH, Irie RF. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Prog Brain Res. 1994; 101:251-275.
13. Kong Y, Li R, Ladisch S. Natural forms of shed tumor gangliosides. Biochim Biophys Acta. 1998; 1394:43-56.
14. Hakansson L, Fredman P, Svennerholm L. Gangliosides in serum immune complexes from tumor-bearing patients. J Biochem. 1985; 98:843-849.
15. Tonegawa Y, Hakomori SI. “Ganglioprotein and globoprotein”: the glycoproteins reacting with anti-ganglioside and anti-globoside antibodies and the ganglioprotein change associated with transformation. Biochem Biophys Res Commun. 1997; 76:9-17.
16. Valentino LA, Ladisch S. Localization of shed human tumor gangliosides: association with lipoproteins. Cancer Res. 1992; 52:810-814.
17. Dolo V, Li R, Dillinger M, et al. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim Biophys Acta. 2000; 1486:265-274.
18. Chu KU, Ravindranath MH, Gonzales A, et al. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer. 2000; 88:1828-1836.
19. Svennerholm L. Quantitative estimation of sialic acid. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 1957; 24:604-611.
20. Schutter EMJ, Visser JJ, van Kamp GJ, et al. The usefulness of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of literature. Tumor Biol. 1992; 13:121-132.
21. Raynes JG. Serum concentration of lipid bound sialic acid and acute phase proteins in patients with cancer and nonmalignant disease. Biomed Pharmacother. 1983; 3:136-138.
22. Voigtmann R, Pokorny J, Meinshausen A. Evaluation and limitations of the lipid-associated sialic acid test for the detection of human cancer. Cancer. 1989; 64:2279-2283.
23. Kloppel TM, Keenan TW, Freeman MJ, et al. Glycolipid bound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. Proc Natl Acad Sci U S A. 1977; 74:3011-3013.
24. Kundu SK, Diego I, Osovitz S, et al. Glycosphingolipids of human plasma. Arch Biochem Biophys. 1985; 238:388-400.
25. Gokmen SS, Kilicli G, Ozcelik F, et al. Serum total and lipid-bound sialic acid levels after acute myocardial infarction. Clin Chem Lab Med. 2000; 38:1249-1255.
26. Dippold WG, Knuth A, Meyer zum Buschenfelde KH. Inflammatory tumor response to monoclonal antibody infusion. Eur J Cancer Clin Oncol. 1985; 21:907-912.
27. 2 with potential for cancer treatment. Cancer Res. 1996; 56:5666-5671.
28. McKallip R, Li R, Ladisch R. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol. 1999; 163:3718-3726.
29. Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest. 1987; 79:1879-1882.
30. Allessandri G, Filippeschi S, Sinibaldi P, et al. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res. 1987; 47:4243-4247.
31. Takahashi K, Ono K, Hirabayashi Y, et al. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol. 1988; 140:3244-3248.
32. 1b. Biochem Biophys Res Commun. 2001; 283:369-373.
33. Bergelson LD. Serum gangliosides as endogenous immunomodulators. Immunol Today. 1995; 46:483-486.
34. Ravindranath MH, Morton DL, Irie RF. An epitope common to gangliosides O-Ac-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 1989; 49:389-397.
35. 3 ratio as an index for the management of melanoma. Cancer. 1991; 67:3029-3035.